KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49%

Daniel Morgensztern

Research output: Contribution to journal › Comment/debate

9 Scopus citations

Fingerprint

Dive into the research topics of 'KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49%'. Together they form a unique fingerprint.